Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality

European Journal of Cancer

Volumn 49, Issue 5, 2013, Pages 1049-1057

  McCowan, C ^a   Munro, A J ^a   Donnan, P T ^a   Steele, R J C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aspirin; Colorectal cancer; Survival

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER SPECIFIC MORTALITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; SOCIAL STATUS; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA; CAUSE OF DEATH; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SCOTLAND; SURVIVAL ANALYSIS; SURVIVORS;

EID: 84874938572     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.024     Document Type: Article

References (45)

1. J.A. Baron, B.F. Cole, and R.S. Sandler A randomized trial of aspirin to prevent colorectal adenomas Obstet Gynecol Surv 58 8 2003 538 539
2. R.S. Sandler, S. Halabi, and J.A. Baron A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer Obstet Gynecol Surv 58 8 2003 539 541
3. R. Benamouzig, J. Deyra, and A. Martin Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 125 2 2003 328 336
4. R.F.A. Logan, M.J. Grainge, V.C. Shepherd, N.C. Armitage, and K.R. Muir Aspirin and folic acid for the prevention of recurrent colorectal adenomas Gastroenterology 134 1 2008 29 38
5. B.F. Cole, R.F. Logan, and S. Halabi Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials J Natl Cancer Inst 101 4 2009 256 266
6. M.M. Bertagnolli, C.J. Eagle, and A.G. Zauber Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 9 2006 873 884
7. N. Arber, C.J. Eagle, and J. Spicak Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 9 2006 885 895
8. J.A. Baron, R.S. Sandler, and R.S. Bresalier A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 6 2006 1674 1682
9. A. Leslie, F.A. Carey, N.R. Pratt, and R.J.C. Steele The colorectal adenoma-carcinoma sequence Br J Surg 89 7 2002 845 860
10. E. Flossmann, P.M. Rothwell, and British Doctors Aspirin Trial and the UK-TIA Aspirin Trial Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369 9573 2007 1603 1613
11. P.M. Rothwell, F.G. Fowkes, and J.F. Belch Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 9759 2011 31 41
12. J. Burn, A.-M. Gerdes, and F. Macrae Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 9809 2011 2081 2087
13. A.T. Chan, S. Ogino, and C.S. Fuchs Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356 21 2007 2131 2142
14. S.D. Markowitz Aspirin and colon cancer-targeting prevention? N Engl J Med 356 21 2007 2195 2198
15. C.E. Eberhart, R.J. Coffey, and A. Radhika Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 4 1994 1183 1188
16. L.T. Soumaoro, H. Uetake, and T. Higuchi Cyclooxygenase-2 expression Clin Cancer Res 10 24 2004 8465 8471
17. J.R. Brown, and R.N. DuBois COX-2: a molecular target for colorectal cancer prevention J Clin Oncol 23 12 2005 2840 2855
18. S. Tomozawa, N.H. Tsuno, and E. Sunami Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer Br J Cancer 83 3 2000 324 328
19. C.S. Williams, A.J.M. Watson, and H. Sheng Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models Cancer Res 60 21 2000 6045 6051
20. C.S. Williams, H. Sheng, and J.A. Brockman A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts Neoplasia 3 5 2001 428 436
21. T. Yamauchi, M. Watanabe, and H. Hasegawa The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer Anticancer Res 23 1A 2003 245 249
22. M. Yao, S. Kargman, and E.C. Lam Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice Cancer Res 63 3 2003 586 592
23. M. Yao, E.C. Lam, C.R. Kelly, W. Zhou, and M.M. Wolfe Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer Br J Cancer 90 3 2004 712 719
24. M. Yao, W. Zhou, and S. Sangha Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer Clin Cancer Res 11 4 2005 1618 1628
25. P.C. Chulada, M.B. Thompson, and J.F. Mahler Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in min mice Cancer Res 60 17 2000 4705 4708
26. A.E. Coghill, P.A. Newcomb, and E.M. Poole Genetic variation in inflammatory pathways is related to colorectal cancer survival Clin Cancer Res 17 22 2011 7139 7147
27. C. Fuchs, J. Meyerhardt, and D. Heseltine Influence of regular aspirin use on survival of patients with stage III colon cancer: findings from intergroup trial CALGB 89803 J Clin Oncol 23 Suppl. 16 2005 3530
28. A.T. Chan, S. Ogino, and C.S. Fuchs Aspirin use and survival after diagnosis of colorectal cancer JAMA 302 6 2009 649 658
29. E. Bastiaannet, K. Sampieri, and O.M. Dekkers Use of aspirin postdiagnosis improves survival for colon cancer patients Br J Cancer 106 9 2012 1564 1570
30. C. McCowan, J. Shearer, and P.T. Donnan Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 11 2008 1763 1768
31. J.A. Zell, A. Ziogas, and L. Bernstein Nonsteroidal anti-inflammatory drugs Cancer 115 24 2009 5662 5671
32. A.E. Coghill, P.A. Newcomb, and P.T. Campbell Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer Gut 60 4 2011 491 498
33. P.M. Rothwell, M. Wilson, and J.F. Price Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 9826 2012 1591 1601
34. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol 13 5 2012 518 527
35. C. Dubé, A. Rostom, and G. Lewin The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force Ann Intern Med 146 5 2007 365 375
36. U.A. Ajani, E.S. Ford, K.J. Greenland, W.H. Giles, and A.H. Mokdad Aspirin use among U.S. adults: behavioral risk factor surveillance system Am J Prev Med 30 1 2006 74 77
37. S.V. Morant, A.D. McMahon, J.G.F. Cleland, P.G. Davey, and T.M. MacDonald Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity Br J Clin Pharmacol 57 2 2004 188 198
38. R.S. Midgley, C.C. McConkey, and E.C. Johnstone Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial J Clin Oncol 28 30 2010 4575 4580
39. D.J. Kerr, J.A. Dunn, and M.J. Langman Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer N Engl J Med 357 4 2007 360 369
40. N.D. Yeomans Aspirin: old drug, new uses and challenges J Gastroenterol Hepatol 26 3 2011 426 431
41. K.C. Lai, S.K. Lam, and K.M. Chu Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 346 26 2002 2033 2038
42. C.H. Hennekens, M.L. Dyken, and V. Fuster Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 96 8 1997 2751 2753
43. INDOX Cancer Research Network. ASCOLT study. < http://indox.org.uk/ research/clinical/ascolt >; 2010.
44. F.V.N. Din, E. Theodoratou, and S.M. Farrington Effect of aspirin and NSAIDs on risk and survival from colorectal cancer Gut 59 12 2010 1670 1679
45. National Cancer Institute (NCI). Oxaliplatin, leucovorin calcium, and fluorouracil with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. < http://clinicaltrials.gov/ct2/ show/NCT01150045 >; 2012.